Preclinical In Vitro and In Vivo Characterization of Synaptic Vesicle 2A–Targeting Compounds Amenable to F-18 Labeling as Potential PET Radioligands for Imaging of Synapse Integrity

Assessing Synaptic Density in Alzheimer Disease With Synaptic Vesicle Glycoprotein 2A Positron Emission Tomographic Imaging

(2018) Ming-Kai Chen et al.   JAMA Neurology

Development and In Vivo Preclinical Imaging of Fluorine-18-Labeled Synaptic Vesicle Protein 2A (SV2A) PET Tracers

(2018) Cristian C. Constantinescu et al.   MOLECULAR IMAGING AND BIOLOGY

Animal models of neurodegenerative diseases

(2018) Ted M. Dawson et al.   NATURE NEUROSCIENCE

Synthesis and in Vivo Evaluation of a Novel PET Radiotracer for Imaging of Synaptic Vesicle Glycoprotein 2A (SV2A) in Nonhuman Primates

(2018) Songye Li et al.   ACS Chemical Neuroscience

Kinetic evaluation and test–retest reproducibility of [11C]UCB-J, a novel radioligand for positron emission tomography imaging of synaptic vesicle glycoprotein 2A in humans

(2017) Sjoerd J Finnema et al.   JOURNAL OF CEREBRAL BLOOD FLOW AND METABOLISM

Tactics for preclinical validation of receptor-binding radiotracers

(2017) Susan Z. Lever et al.   NUCLEAR MEDICINE AND BIOLOGY

Synaptic Vesicle Glycoprotein 2A Ligands in the Treatment of Epilepsy and Beyond

(2016) Wolfgang Löscher et al.   CNS DRUGS

Enabling Efficient Positron Emission Tomography (PET) Imaging of Synaptic Vesicle Glycoprotein 2A (SV2A) with a Robust and One-Step Radiosynthesis of a Highly Potent 18F-Labeled Ligand ([18F]UCB-H)

(2016) Corentin Warnier et al.   JOURNAL OF MEDICINAL CHEMISTRY

Synthesis and Preclinical Evaluation of 11C-UCB-J as a PET Tracer for Imaging the Synaptic Vesicle Glycoprotein 2A in the Brain

(2016) N. B. Nabulsi et al.   JOURNAL OF NUCLEAR MEDICINE

Imaging synaptic density in the living human brain

(2016) Sjoerd J. Finnema et al.   Science Translational Medicine

Optimizing Central Nervous System Drug Development Using Molecular Imaging

(2015) RJ Hargreaves et al.   CLINICAL PHARMACOLOGY & THERAPEUTICS

Brivaracetam, a selective high-affinity synaptic vesicle protein 2A (SV2A) ligand with preclinical evidence of high brain permeability and fast onset of action

(2015) Jean-Marie Nicolas et al.   EPILEPSIA

Synaptic vesicle glycoprotein 2A modulates vesicular release and calcium channel function at peripheral sympathetic synapses

(2014) Christian Vogl et al.   EUROPEAN JOURNAL OF NEUROSCIENCE

Synaptic vesicle protein 2A: basic facts and role in synaptic function

(2013) Julieta Griselda Mendoza-Torreblanca et al.   EUROPEAN JOURNAL OF NEUROSCIENCE

Molecular machines governing exocytosis of synaptic vesicles

(2012) Reinhard Jahn et al.   NATURE

Binding characteristics of brivaracetam, a selective, high affinity SV2A ligand in rat, mouse and human brain: Relationship to anti-convulsant properties

(2011) Michel Gillard et al.   EUROPEAN JOURNAL OF PHARMACOLOGY

In vivo site-directed radiotracers: a mini-review

(2008) Shil Patel et al.   NUCLEAR MEDICINE AND BIOLOGY